P
GMAB icon

Pitcairn’s Genmab GMAB Stock Holding History

Pitcairn’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-16,535
Closed -$507K – 225
2025
Q3 		$507K Buy
16,535
+4,269
+35% +$104K 0.04% 345
2025
Q2 		$253K Sell
12,266
-3,104
-20% -$63.7K 0.02% 607
2025
Q1 		$301K Sell
15,370
-3,171
-17% -$66.5K 0.02% 576
2024
Q4 		$387K Buy
18,541
+7,640
+70% +$168K 0.02% 505
2024
Q3 		$266K Sell
10,901
-1,168
-10% -$31.2K 0.02% 624
2024
Q2 		$303K Sell
12,069
-5,221
-30% -$148K 0.02% 585
2024
Q1 		$517K Buy
17,290
+1,960
+13% +$57.6K 0.03% 430
2023
Q4 		$488K Buy
15,330
+3,192
+26% +$100K 0.04% 407
2023
Q3 		$428K Buy
+12,138
New +$463K 0.04% 412

Other funds holding GMAB

OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
HL
Harding Loevner Bridgewater, New Jersey $9.72B AUM 22.38% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Pitcairn's GMAB Position: Q4 2025 in Review

Pitcairn sold out of Genmab (GMAB) in Q4 2025, closing a stake of 16,535 shares — an estimated $507K sold.

Pitcairn first reported a position in GMAB in Q3 2023 and held it in 9 quarters. The position peaked at $517K in Q1 2024. 292 funds tracked by Wall St. Rank hold GMAB as of Q4 2025.

  • Pitcairn reported no remaining Genmab position as of Q4 2025 after selling out during the quarter.
  • Pitcairn sold 16,535 Genmab shares in Q4 2025, an estimated $507K.
  • Pitcairn first reported a position in Genmab in Q3 2023 and held it in 9 quarters.
  • Pitcairn's Genmab position peaked at $517K in Q1 2024.
  • 292 funds tracked by Wall St. Rank held Genmab as of Q4 2025.

Based on Pitcairn's 13F filing for Q4 2025.